Ad-hoc | 1 December 2010 07:23
Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous
01.12.2010 07:23
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Fresenius Medical Care and Galenica form renal pharmaceutical company
Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA today announced
the formation of a new renal pharmaceutical company named Vifor-Fresenius
Medical Care Renal Pharma Ltd. and designed to develop and distribute on a
world wide basis products to treat iron deficiency anaemia and bone mineral
metabolism for pre-dialysis and dialysis patients. The products of the new
company will include Venofer(R) and Ferinject(R) (Injectafer(R), the brand
name for Ferinject(R) in the USA) within the field of dialysis and
pre-dialysis (CKD stage III - V) as well as PA21, a novel iron-based
phosphate binder. The newly formed company, with headquarters in
Switzerland, extends existing agreements with Galenica. The existing
customer and distribution agreements will stay in place.This investment
allows Fresenius Medical Care to take the next major implementation step in
its renal pharmaceutical strategy. Fresenius Medical Care will hold a 45%
share in the new company. The transaction is subject to final anti-trust
approval in certain regions.
Fresenius SE (WKN 578560, 578563) holds approximately 36% of Fresenius
Medical Care AG & Co. KGaA's capital.
Fresenius Medical Care AG & Co. KGaA,
Represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., December 01, 2010
01.12.2010 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Deutschland
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Indices: DAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Hannover, Stuttgart, Hamburg, München, Düsseldorf;
Terminbörse EUREX; Foreign Exchange(s) NYSE
End of Announcement DGAP News-Service
---------------------------------------------------------------------------